InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
surf1944 Free
05/16/10 10:11 PM
profile icon
surf1944 Free
04/22/10 6:43 PM
profile icon
surf1944 Free
04/19/10 9:41 AM
profile icon
surf1944 Free
03/29/10 5:36 PM
profile icon
surf1944 Free
03/01/10 7:41 AM
profile icon
surf1944 Free
12/22/09 8:53 AM
profile icon
Swizzer13 Free
11/07/08 2:11 AM
profile icon
Swizzer13 Free
09/29/08 3:03 PM
profile icon
Slyhunter Free
06/03/08 10:54 AM
profile icon
Swizzer13 Free
12/07/07 10:50 AM
profile icon
surf1944 Free
12/07/07 10:05 AM
profile icon
Swizzer13 Free
12/07/07 10:01 AM
profile icon
surf1944 Free
11/05/07 11:32 AM
profile icon
Swizzer13 Free
11/05/07 11:21 AM
profile icon
Swizzer13 Free
10/24/07 7:00 AM
profile icon
Swizzer13 Free
10/22/07 7:15 AM
profile icon
surf1944 Free
10/22/07 7:05 AM
profile icon
Swizzer13 Free
10/22/07 6:25 AM
profile icon
surf1944 Free
10/18/07 7:49 PM
profile icon
Swizzer13 Free
08/31/07 6:36 AM
profile icon
Swizzer13 Free
06/04/07 6:44 AM
profile icon
Swizzer13 Free
05/31/07 6:45 AM
profile icon
Swizzer13 Free
05/28/07 11:38 AM
profile icon
Swizzer13 Free
05/26/07 7:32 PM
profile icon
Swizzer13 Free
05/26/07 11:01 AM
profile icon
Swizzer13 Free
05/25/07 5:22 PM
profile icon
Swizzer13 Free
05/25/07 8:19 AM
profile icon
ker7502 Free
06/27/06 2:42 PM

OSI Pharmaceuticals Inc. (Osip) RSS Feed

Followers
1
Posters
4
Posts (Today)
0
Posts (Total)
30
Created
06/27/06
Type
Free
Moderators

http://www.osip.com

http://finance.yahoo.com/q/ks?s=OSIP+Key+Statistics

OSI Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of oncology, ophthalmology, and diabetic diseases in the United States. Its product Tarceva, an oral small molecule inhibitor of the epidermal growth factor receptor. The company also offers Macugen for the treatment of neovascular age-related macular degeneration; Novantrone, an anthracenedione, which is used as intravenous chemotherapy agent, as well as for the treatment of nonlymphocytic leukemia, and the relief of pain associated with hormone refractory prostate cancer; and Gelclair, a bioadherant oral gel for the relief of pain associated with oral mucositis. In addition, the company offers OSI-930, a tyrosine kinase inhibitor, designed to target cancer cell proliferation and blood vessel growth, or angiogenesis, in selected tumors completed Phase I dose escalation studies; OSI-906, a tyrosine kinase inhibitor, that acts as a selective inhibitor and stimulates proliferation, enables oncogenic transformation and suppresses apoptosis; and PSN9301 is in Phase II clinical trials for the treatment of type 2 diabetes. In addition, OSI Pharmaceuticals, through its collaborative drug discovery program with Pfizer, develops CP-547,632, which targets vascular endothelial growth factor receptor and is in Phase II trials; and CP-868,596 that targets tumor derived angiogenesis and is in Phase I trials. Further, through its subsidiary, provides diabetes and obesity treatment in the United Kingdom. The company also has collaboration agreements with Cold Spring Harbor Laboratory; Genentech, Inc.; and Roche. OSI Pharmaceuticals was founded in 1983 and is headquartered in Melville, New York.

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Osip Latest News
  • No Recent News Available for this company!
New Post